Skip to content

Aurobindo receives FDA approval for enalapril maleate oral solution

EAST WINDSOR, N.J. – Aurobindo Pharma Limited has received final approval from U.S.

Table of Contents

EAST WINDSOR, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application enalapril maleate oral solution, 1 mg/mL Aurobindo Pharma’s enalapril maleate oral solution, are an AB-rated generic equivalent to the reference listed drug (RLD), Epaned Oral Solution, manufactured by Azurity Pharmaceuticals, Inc.

Enalapril maleate oral solution are indicated for the treatment of:
• Hypertension
• Symptomatic heart failure
• Asymptomatic left ventricular dysfunction

Enalapril maleate oral solution has an estimated market size of US $19.9 Million for the twelve months ending Nov 2023, as per IQVIA.

Comments

Latest

Unanimously, FTC issues second pounding of big PBMs

Unanimously, FTC issues second pounding of big PBMs

NACDS: “The problems of big-PBM tactics remain obvious. The bipartisan and broadly-backed solutions remain ready in Congress. Time is wasting – as is Americans’ money. It’s time to stop this rip-off and to deliver a win for the American people.”